Merck jumps on profit beat as Bristol Myers Squibb slips to a loss
Merck & Co Inc (NYSE:MRK, ETR:6MK), the pharmaceutical firm, saw its shares tick 3.5% higher after its cancer drug Keytruda…
53,945€
-1,78%
Echtzeit-Aktienkurs Bristol-Myers Squibb Co.
Bid:
Ask:
Nachrichten zur Bristol-Myers Squibb Co. Aktie
Bristol Myers Squibb beats on revenue, launches $1.5 billion cost cuts as it posts quarterly loss
Bristol Myers Squibb said the charges primarily reflect its acquisition of Karuna Therapeutics and collaboration agreement with SystImmune.…
Bristol-Myers Squibb stock slips despite earnings beat By Investing.com
Bristol-Myers Squibb stock slips despite earnings beat…
Bristol-Myers Squibb earnings beat by $0.07, revenue topped estimates By Investing.com
Bristol-Myers Squibb earnings beat by $0.07, revenue topped estimates…
Bristol Myers posts quarterly loss, revenue rises 5%
Bristol Myers Squibb on Thursday reported a first-quarter loss as charges related to its recent acquisitions of Karuna Therapeutics, RayzeBio…
Pharmabranche: Neuer Novartis-Chef kommt von Bristol Myers Squibb
Jörg Reinhardt tritt nach zwölf Jahren als Novartis-Chef zurück. Sein Nachfolger steht bereits fest. Er kommt von einem direkten Konkurrenten.…
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Anthos Therapeutics, Inc. (Anthos), is a clinical-stage company developing innovative…
Is Bristol Myers Squibb A Buy At These Bottom Levels?
…
Bristol Myers Squibb and Cellares reach $380 million supply deal for CAR-T therapies By Reuters
Bristol Myers Squibb and Cellares reach $380 million supply deal for CAR-T therapies…
Got $500? 3 Healthcare Stocks to Buy and Hold Forever @themotleyfool #stocks $ISRG $BMY $NVO
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.…
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.…
Global CAR T-Cell Therapy Market Size To Worth USD 21.92 Billion By 2033 | CAGR of 17.72%
The Global CAR T-Cell Therapy Market Size was Valued at USD 4.29 Billion in 2023 and the Worldwide CAR T-Cell…
Biotech im Visier - Bristol-Myers Squibb, Formycon, MorphoSys, Vidac Pharma Aktie
Für viele Pharma- und Biotechaktionäre hat dieser Sektor einen ganz besonderen Charme. In dieser hochspekulativen Branche liegen Erfolg und Misserfolg…
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF? @themotleyfool #stocks $BMY $LLY $^GSPC $NVO $VOO
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard…
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard…
Global Chemotherapy Market Size To Exceed USD 16.2 Billion By 2033 | CAGR of 6.54%
The Global Chemotherapy Market Size was Valued at USD 8.6 Billion in 2023 and the Worldwide Chemotherapy Market Size is…
Bristol Myers Squibb: Seriously Undervalued At Peak Pessimism (Rating Upgrade)
…
Übernahmewelle rollt: Jetzt drei weitere heiße Kandidaten kennenlernen
87 Prozent, 97 Prozent und 105 Prozent – diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…
Übernahmewelle rollt: Jetzt drei weitere heiße Kandidaten kennenlernen
87 Prozent, 97 Prozent und 105 Prozent - diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…
Übernahmewelle rollt: Jetzt drei weitere heiße Kandidaten kennenlernen
87 Prozent, 97 Prozent und 105 Prozent – diese Aufschläge haben die großen Pharma-Firmen Eli Lilly, Astrazeneca und Bristol Myers…
Bristol-Myers Squibb Is A Speculative Buy On Price Action (Technical Analysis)
…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
NEW YORK, March 31, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Bristol Myers Squibb: The Comeback Is Unfolding
…
Is Bristol Myers Squibb Stock a Buy?
The company is going through a rough patch.…
[Latest] Global PARP Inhibitors Market Size/Share Worth USD 23.5 Billion by 2032 at a 12.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY
NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…
Bristol-Myers Squibb Is Not A Buy For Me
…
Bristol Myers Squibb completes Karuna Therapeutics buyout By Investing.com
Bristol Myers Squibb completes Karuna Therapeutics buyout…
Bristol-Myers Squibb Company (BMY) Barclays 26th Annual Global Healthcare Conference (Transcript)
…
Karuna Therapeutics set to merge with Bristol-Myers Squibb By Investing.com
Karuna Therapeutics set to merge with Bristol-Myers Squibb…
Bristol-Myers Squibb: Großes Interesse an ADC-Playern - Tubulis holt hochkarätige Investoren an Bord - Aktienanalyse
Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär":
Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Bristol-Myers Squibb Company…
Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)
…
Bristol Myers, Moderna und Roche ziehen Anti Virus-Index auf Jahreshoch
Der Global Anti Virus Health Net Return Index hat in den zurückliegenden Tagen von der Mehrheit der Indexmitglieder Rückenwind erhalten.…
Societe Generale cuts Bristol-Myers Squibb to Hold By Investing.com
Societe Generale cuts Bristol-Myers Squibb to Hold…
Bristol-Myers Squibb: Finally Trending Up
…
Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024, Featuring Sanofi, Bristol Myers Squibb, Abbott Laboratories, Takeda Pharmaceutical and Amgen
Dublin, March 08, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy Induced Peripheral Neuropathy Treatment Global Market Report 2024" has…
Bristol-Myers Squibb: Turnaround Expected
…
Bristol-Myers Squibb: Compelling Value From The New Products Portfolio And 4.5% Yield
…
Bristol-Myers Squibb Company (BMY) 44th Annual TD Cowen Healthcare Conference (Transcript)
…
Follicular Lymphoma Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies - AbbVie, Genmab, Novartis, Allogene Therapeutics, Pfizer, Genentech, Incyte Corporation, Bristol-Myers Squibb
The dynamics of the follicular lymphoma market are anticipated to change in the coming years owing to the improvement in…
Bristol Myers Squibb completes RayzeBio acquisition By Investing.com
Bristol Myers Squibb completes RayzeBio acquisition…
Milliardendeal: Bristol-Myers will Biopharmaunternehmen Karuna kaufen
NEW YORK (dpa-AFX) - Der US-Pharmakonzern Bristol-Myers Squibb will seinen Konkurrenten Karuna Therapeutics übernehmen. Die…
Zunehmende Konkurrenz für Krebsmedikament macht Pharmakonzern BMS zu schaffen
NEW YORK (dpa-AFX) - Der US-Pharmakonzern Bristol Myers Squibb (BMS) kämpft weiter mit zunehmender Konkurrenz…